PARP inhibitors show promise for hard-to-treat breast cancers
Published: 25 Jun 2009
Views: 12544
Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK
A study reports that women with BRCA deficient advanced breast cancer experienced tumour shrinkage after receiving the PARP inhibitor olaparib as a single agent.
- Categories:
- Breast
Related Videos
Breast cancer roundup from ASCO 2021
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
18 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 4 and 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
16 Jun 2021
Clinically sufficient vitamin D levels at breast cancer diagnosis and survival o...
Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA
10 Jun 2021
Olaparib improves disease-free survival in high-risk early-stage HER2-negative b...
Prof Andrew Tutt - Institute of Cancer Research, London, UK
4 Jun 2021
Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems
Special issue authors and funders
16 May 2021
Women's cancers in the Democratic Republic of Congo
Prof Richard Sullivan - Kings College London, London, UK
12 May 2021
OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
7 May 2021
SMMART Program: A multi-omics tumour board with a focus on breast cancer
Dr Ben Kong - Oregon Health & Science University, Portland, USA
13 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
13 Apr 2021
